Vir Biotechnology to Present Complete Phase 2 Solstice Data for Hepatitis Delta
VIR has more than doubled off its 52-week low of $4.155.
Summary
Vir Biotechnology announced it will present complete Week 96 data from its Phase 2 Solstice clinical trial for Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026. This announcement signals an important upcoming catalyst for the company, as the full data from a mid-stage clinical trial can significantly influence investor perception of the drug's potential and the company's future prospects. While the specific results are not yet disclosed, traders will be closely monitoring the presentation for insights into the efficacy and safety profile of the treatment. This news provides new information regarding a key clinical program, distinct from the recent Q1 financial results and the Astellas collaboration.
At the time of this announcement, VIR was trading at $8.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $4.16 to $11.66. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.